Heart Failure Management Guidelines

Introduction to Heart Failure Management

The American Heart Association recommends the initial management for heart failure with reduced ejection fraction (HFrEF) to include four foundational medication classes: SGLT2 inhibitors, beta-blockers, mineralocorticoid receptor antagonists (MRAs), and either an angiotensin receptor-neprilysin inhibitor (ARNI), ACE inhibitor, or ARB, while management for heart failure with preserved ejection fraction (HFpEF) should focus on SGLT2 inhibitors and diuretics for symptom control 1, 2

The American College of Cardiology recommends ARNI (sacubitril/valsartan) as first-line therapy for patients with HFrEF and NYHA class II-III symptoms to reduce morbidity and mortality 1
If ARNI is not feasible, the American Heart Association recommends an ACE inhibitor for patients with previous or current symptoms of chronic HFrEF to reduce morbidity and mortality 1
For patients intolerant to ACE inhibitors due to cough or angioedema, the European Society of Cardiology recommends an ARB when ARNI is not feasible 1
Beta-blockers (specifically bisoprolol, carvedilol, sustained-release metoprolol succinate, or nebivolol) should be initiated for all patients with HFrEF regardless of symptom severity, as recommended by the American College of Cardiology 3, 4
Mineralocorticoid receptor antagonists (spironolactone or eplerenone) are recommended for patients with NYHA class II-IV HF who can be carefully monitored for renal function and potassium levels, according to the American Heart Association 1
SGLT2 inhibitors should be added to the treatment regimen regardless of diabetes status, as recommended by the American Diabetes Association 1, 2

The European Society of Cardiology recommends SGLT2 inhibitors as first-line therapy for HFpEF based on evidence from recent trials showing significant reductions in heart failure hospitalizations and worsening heart failure events 5, 2
Diuretics should be used for symptomatic relief of fluid retention, with loop diuretics being the mainstay for acute volume management, as recommended by the American College of Cardiology 5, 2
MRAs, particularly spironolactone, can be considered in appropriate patients to reduce heart failure hospitalizations, according to the European Heart Journal 5, 2
ARNIs or ARBs may be considered in selected patients, particularly those with lower ejection fraction within the preserved range or women, as recommended by the American Heart Association 5, 2

Aggressive management of comorbidities is crucial in HFpEF, including hypertension, diabetes mellitus, obesity, atrial fibrillation, coronary artery disease, chronic kidney disease, and obstructive sleep apnea, as recommended by the European Society of Cardiology 5, 2
Beta-blockers are not recommended as primary HFpEF therapy unless specific indications exist, such as rate control for atrial fibrillation, according to the American College of Cardiology 5, 2
Inadequate dose titration of medications often results in subtherapeutic dosing and reduced efficacy, as noted by the American Heart Association 1
Excessive diuresis can lead to electrolyte abnormalities, worsening renal function, and hypotension, as warned by the European Heart Journal 5
Monitoring of renal function and electrolytes is essential, particularly when using MRAs, as hyperkalemia is a common adverse effect, according to the American College of Cardiology 1
For HFpEF, there is a tendency to overuse medications proven only for HFrEF; treatment should focus on evidence-based therapies for HFpEF specifically, as recommended by the European Society of Cardiology 5, 2